摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

m-(but-3-enyloxy)aniline | 1152500-24-7

中文名称
——
中文别名
——
英文名称
m-(but-3-enyloxy)aniline
英文别名
3-(But-3-en-1-yloxy)aniline;3-but-3-enoxyaniline
m-(but-3-enyloxy)aniline化学式
CAS
1152500-24-7
化学式
C10H13NO
mdl
MFCD20291719
分子量
163.219
InChiKey
KDVIBXRCWHRGGD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    290.4±23.0 °C(Predicted)
  • 密度:
    1.018±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    12
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    m-(but-3-enyloxy)anilinepotassium carbonateN,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺乙腈 为溶剂, 反应 5.0h, 生成
    参考文献:
    名称:
    有害生物防除方法
    摘要:
    提供有害生物防治方法。例如,涉及将下式化合物或其N氧化物或它们的盐的有效量应用于有害生物、有害生物栖息地、植物或植物栽培载体的过程的有害生物防治方法。【选择图】无
    公开号:
    JP2021165297A
  • 作为产物:
    描述:
    3-(but-3-enyloxy)nitrobenzene铁粉溶剂黄146 作用下, 以 为溶剂, 以76%的产率得到m-(but-3-enyloxy)aniline
    参考文献:
    名称:
    ω-芳氧基和芳氨基连接的α,β-不饱和醛的催化不对称分子内氢芳基化反应
    摘要:
    经济的方法:苯酚和苯胺衍生的烯类的首次有机催化不对称分子内氢芳基化为对映异构的二价铬和四氢喹啉提供了一种最直接,最经济的方法(ee高达96%;参见方案)。
    DOI:
    10.1002/chem.200802722
点击查看最新优质反应信息

文献信息

  • Catalytic Asymmetric Intramolecular Hydroarylations of ω-Aryloxy- and Arylamino-Tethered α,β-Unsaturated Aldehydes
    作者:Hai-Hua Lu、Hui Liu、Wei Wu、Xu-Fan Wang、Liang-Qiu Lu、Wen-Jing Xiao
    DOI:10.1002/chem.200802722
    日期:2009.3.9
    Economical approach: The first organocatalytic asymmetric intramolecular hydroarylation of phenol‐ and aniline‐derived enals offers one of the most straightforward and atom‐economic approaches to enantioriched chromans and tetrahydroquinolines (up to 96 % ee; see scheme).
    经济的方法:苯酚和苯胺衍生的烯类的首次有机催化不对称分子内氢芳基化为对映异构的二价铬和四氢喹啉提供了一种最直接,最经济的方法(ee高达96%;参见方案)。
  • Design of postmetallocene catalytic systems of arylimine type for olefi n polymerization: XV. Synthesis of (N-Aryl)salicylaldimine ligands containing a but-3-enyloxy group and their complexes with titanium(IV) dichloride
    作者:I. I. Oleinik、I. V. Oleinik、S. S. Ivanchev、G. A. Tolstikov
    DOI:10.1134/s1070428013080095
    日期:2013.8
    A series of (N-aryl)salicylaldimines was synthesized by the reaction of salicylaldehydes substituted in the positions 3 and 5 by bulky tert-butyl or α-cumyl groups with hydrochlorides of o-, m-, and p-(but-3-enyloxy) aniline in the presence of triethylamine. The obtained compounds formed by the reaction with TiCl2(OPr-i)2 complexes of titanium(IV) dichloride L2TiCl2.
    一系列的(ñ -芳基)水杨醛二胺通过水杨醛在位置取代反应合成3和5由笨重叔丁基或α枯基与盐酸的ø - ,间- ,和p - (丁-3-三乙胺存在下的苯氧基)苯胺。通过与二氯化钛(IV)L 2 TiCl 2的TiCl 2(OPr- i)2配合物反应形成了所获得的化合物。
  • Design of postmetallocene catalytic systems of arylimine type for olefin polymerization: XVII. Synthesis of methoxy-substituted (p-aryl)salicylaldimines containing ω-alkenyloxy group, and their complexes with titanium(IV) dichloride
    作者:I. I. Oleinik、I. V. Oleinik、S. S. Ivanchev、G. A. Tolstikov
    DOI:10.1134/s1070428014110050
    日期:2014.11
    Reaction of 5-methoxy-substituted salicylic aldehydes containing in the position 3 tert-butyl, 2-phenylpropan-2-yl, or 1-phenylethyl groups with m- and p-allyloxy-, (but-3-enyloxy)-, (pent-4-enyloxy)anilines without solvent in an open system at 130°C afforded a series of (N-aryl)salicylaldimines L that with TiCl2 (OPr-i)2 formed complexes of titanium(IV) dichloride L2TiCl2.
    在3位叔丁基,2-苯基丙烷-2-基或1-苯基乙基上的5-甲氧基取代的水杨醛与m-和p-烯丙氧基-(but-3-enyloxy)-,(在没有溶剂的情况下,在130°C的开放系统中进行戊-4-烯氧基)苯胺制得的一系列(N-芳基)水杨醛亚胺L与TiCl 2(OPr- i)2形成二氯化钛(IV)L 2 TiCl 2的配合物。
  • METHOD FOR CONTROLLING PHAKOPSORA PACHYRHIZI HAVING RESISTANCE AGAINST QoI FUNGICIDE
    申请人:SUMITOMO CHEMICAL COMPANY, LIMITED
    公开号:US20230127143A1
    公开(公告)日:2023-04-27
    The present invention provides a method for controlling a soybean rust fungus having an amino acid substitution of F129L on mitochondrial cytochrome b protein. According to the present invention, a compound represented by formula (I) [wherein R 1 represents a C1-C3 chain hydrocarbon group and so on, n is 0, 1, 2 or 3, and when is 2 or 3, a plural of R 2 may be identical to or different from each other, and R 2 represents a C1-C3 chain hydrocarbon group and so on, Q represents a group represented by Q1 (where • represents a binding site to a benzene ring) and so on, L 1 represents CH 2 or an oxygen atom, and E represents a C1-C6 alkyl group and so on.] can use to control a soybean rust fungus having an amino acid substitution of F129L on mitochondrial cytochrome b protein.
  • Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
    作者:Anthony D. William、Angeline C.-H. Lee、Stéphanie Blanchard、Anders Poulsen、Ee Ling Teo、Harish Nagaraj、Evelyn Tan、Dizhong Chen、Meredith Williams、Eric T. Sun、Kee Chuan Goh、Wai Chung Ong、Siok Kun Goh、Stefan Hart、Ramesh Jayaraman、Mohammed Khalid Pasha、Kantharaj Ethirajulu、Jeanette M. Wood、Brian W. Dymock
    DOI:10.1021/jm200326p
    日期:2011.7.14
    Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2(V617F)), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (ME). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2(WT) and JAK2(V617F), respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for ME and lymphoma.
查看更多